Tags

Type your tag names separated by a space and hit enter

Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells.
Front Immunol. 2021; 12:726909.FI

Abstract

Mesenchymal stem cells (MSCs) have been widely used in preclinical and clinical trials for various diseases and have shown great potential in the treatment of sepsis and coronavirus disease (COVID-19). Inflammatory factors play vital roles in the pathogenesis of diseases. The interaction between inflammatory factors is extremely complex. Once the dynamics of inflammatory factors are unbalanced, inflammatory responses and cytokine storm syndrome develop, leading to disease exacerbation and even death. Stem cells have become ideal candidates for the treatment of such diseases due to their immunosuppressive and anti-inflammatory properties. However, the mechanisms by which stem cells affect inflammation and immune regulation are still unclear. This article discusses the therapeutic mechanism and potential value of MSCs in the treatment of sepsis and the novel COVID-19, outlines how MSCs mediate innate and acquired immunity at both the cellular and molecular levels, and described the anti-inflammatory mechanisms and related molecular pathways. Finally, we review the safety and efficacy of stem cell therapy in these two diseases at the preclinical and clinical levels.

Authors+Show Affiliations

Medical School of Chinese PLA, Beijing, China. Department of Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China.Medical School of Chinese PLA, Beijing, China. Department of Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China.Health Care Office, Chinese PLA General Hospital, Beijing, China.Department of Basic Medicine, Graduate School, Chinese PLA General Hospital, Beijing, China.Department of Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China.Department of Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China.Medical School of Chinese PLA, Beijing, China. Department of Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China.Medical School of Chinese PLA, Beijing, China. Department of Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China.School of Public Health, Capital Medical University, Beijing, China.Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.Medical School of Chinese PLA, Beijing, China. Department of Critical Care Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing, China.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34394132

Citation

Wang, Lu, et al. "Regulation of Inflammatory Cytokine Storms By Mesenchymal Stem Cells." Frontiers in Immunology, vol. 12, 2021, p. 726909.
Wang L, Li Y, Xu M, et al. Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells. Front Immunol. 2021;12:726909.
Wang, L., Li, Y., Xu, M., Deng, Z., Zhao, Y., Yang, M., Liu, Y., Yuan, R., Sun, Y., Zhang, H., Wang, H., Qian, Z., & Kang, H. (2021). Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells. Frontiers in Immunology, 12, 726909. https://doi.org/10.3389/fimmu.2021.726909
Wang L, et al. Regulation of Inflammatory Cytokine Storms By Mesenchymal Stem Cells. Front Immunol. 2021;12:726909. PubMed PMID: 34394132.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells. AU - Wang,Lu, AU - Li,Yun, AU - Xu,Moyan, AU - Deng,Zihui, AU - Zhao,Yan, AU - Yang,Mengmeng, AU - Liu,Yuyan, AU - Yuan,Rui, AU - Sun,Yan, AU - Zhang,Hao, AU - Wang,Heming, AU - Qian,Zhirong, AU - Kang,Hongjun, Y1 - 2021/07/29/ PY - 2021/06/17/received PY - 2021/07/14/accepted PY - 2021/8/16/entrez PY - 2021/8/17/pubmed PY - 2021/8/26/medline KW - COVID-19 KW - cytokine storm syndrome KW - immune system KW - mesenchymal stem cells KW - sepsis SP - 726909 EP - 726909 JF - Frontiers in immunology JO - Front Immunol VL - 12 N2 - Mesenchymal stem cells (MSCs) have been widely used in preclinical and clinical trials for various diseases and have shown great potential in the treatment of sepsis and coronavirus disease (COVID-19). Inflammatory factors play vital roles in the pathogenesis of diseases. The interaction between inflammatory factors is extremely complex. Once the dynamics of inflammatory factors are unbalanced, inflammatory responses and cytokine storm syndrome develop, leading to disease exacerbation and even death. Stem cells have become ideal candidates for the treatment of such diseases due to their immunosuppressive and anti-inflammatory properties. However, the mechanisms by which stem cells affect inflammation and immune regulation are still unclear. This article discusses the therapeutic mechanism and potential value of MSCs in the treatment of sepsis and the novel COVID-19, outlines how MSCs mediate innate and acquired immunity at both the cellular and molecular levels, and described the anti-inflammatory mechanisms and related molecular pathways. Finally, we review the safety and efficacy of stem cell therapy in these two diseases at the preclinical and clinical levels. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/34394132/Regulation_of_Inflammatory_Cytokine_Storms_by_Mesenchymal_Stem_Cells_ DB - PRIME DP - Unbound Medicine ER -